COMPARISON OF ANTIRETROVIRAL SCHEMES USED IN INITIAL THERAPY FOR TREATMENT OF HIV/AIDS

Luana LENZI, Astrid WIENS, Roberto PONTAROLO

Resumo


A problem of highly active antiretroviral therapy (HAART) in HIV patients is their adherence to treatment. The aim of this study was to compare the schemes adopted in the initial therapy of these treatments with their adherence, changes in HAART schemes and treatment costs. The study included patients over 16 years old, HIV positive, in treatment for more than 30 days. Adherence to HAART was calculated based on the withdrawal of the drug, which was related to the total treatment time. We evaluated how many patients changed HAART. The costs of each regimen were also estimated and related to the benefit of each treatment. 142 patients who were between 38 and 1,150 days of treatment were included (57.7% women). The schemes with lower costs, highest adherence and greater benefit were efavirenz with biovir and efavirenz with lamivudine and tenofovir. This study suggested the advantageous therapeutic regimens to start of treatment, both from the point of view of patients and the health system. This information can serve as a subsidy to clinicians in the decision of starting HAART.


Texto completo:

PDF

Apontamentos

  • Não há apontamentos.


Direitos autorais 2013 Acta Biomédica Brasiliensia

Licença Creative Commons
Este obra está licenciado com uma Licença Creative Commons Atribuição-CompartilhaIgual 4.0 Internacional.